Navigation Links
Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
Date:10/8/2009

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations at the following conferences:

  • AdvaMed 2009 on Tuesday, October 13, 2009 at 10:00 a.m. Eastern Time at the Walter E. Washington Convention Center in Washington, D.C.
  • BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at 10:00 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego, California.

"The hallmark of Adnavance's direct detection technology is its simplicity; it doesn't require PCR, light detection, or sample pre-treatment. We are highly encouraged by our initial data supporting the utility of our technology and its potential for use in medium complexity laboratories," said Dr. White. "Our mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of its proprietary technology that allows direct-detection of DNA targets in human clinical samples. The Company is located in San Diego, CA. The Company's patented technology is based on the change in surface charge on a gold electrode when DNA targets hybridize with capture probes anchored to the electrode surface. The Company uses a microarray of electrodes in an electrochemical cell to detect the target DNA and the inherent ultra-sensitivity of electrochemical measurements obviates the need for target amplification used in current molecular-based tests. In addition, the electrochemical measurement simplifies the medical device and eliminates sample pre-treatment steps required for PCR-based tests. Adnavance scientists were the first to discover the surface charge phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com

SOURCE Adnavance Technologies Inc.


'/>"/>
SOURCE Adnavance Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
2. ReBuilder Medical Technologies, Inc. Hiring! Increases Staff by 40%
3. Wound Management Technologies Acquires Resorbable Orthopedics
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
6. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
9. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017  Rosen ... the filing of a class action lawsuit on behalf ... ALXN ) from February 10, 2014 through November ... to recover damages for Alexion investors under the federal ... action, go to http://rosenlegal.com/cases-991.html or call ...
(Date:1/13/2017)... , Jan. 13, 2017 Over the last 10 years ... rapidly (6% – 10% yoy) and are expected to deliver remarkable future ... region, followed by Thailand , the Philippines ... and Singapore .  A member of the G20 and ... almost 40% of the SEA,s economic output and the largest pharma manufacturing ...
(Date:1/13/2017)... -- ... Research and Markets has announced the addition of the ... offering. The disease is divided into two categories ... melanoma, which can be treated with surgery, and advanced melanoma, which ... therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR Group, a ... announce that it will be assisting HackensackUMC Mountainside with its public relations efforts, ... servicing all surrounding towns. The firm will be working closely with HackensackUMC Mountainside’s ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... NJ (PRWEB) , ... January 13, 2017 , ... ... sale companions, will be showcasing the next generation companion scanner and data collector at ... The new KDC270 has been created as an answer to the market’s need for ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is proud ... Smith, RD, LD, will serve on the 2017 TBCC Board. , Kris ... and one year as Vice President. She will oversee the newly elected board of ...
Breaking Medicine News(10 mins):